US Biosimilar Sponsors Seek Off-The-Record Discussions

Biosimilar Sponsors Want Off-The-Record Labeling Discussions With FDA

 
• By Derrick Gingery

Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions without written record; negotiations for BsUFA III may be opportunity to create such a process.

Meeting
IP issues often are part of biosimilar labeling carve-out discussions, and could be used in future patent litigation if on the record, sponsors say • Source: Shutterstock

More from Biosimilars

More from Products